AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD

NCT ID: NCT05683379

Last Updated: 2025-11-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-12-20

Study Completion Date

2026-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observational screening study to evaluate the prevalence of anti-adeno-associated serotype 8 (AAV8) antibodies in participants with Duchenne muscular dystrophy (DMD).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an observational screening study to evaluate the prevalence of anti-adeno-associated serotype 8 (AAV8) antibodies in participants with Duchenne muscular dystrophy (DMD). Information collected in this study may be used to identify potential participants for DMD investigational gene therapy clinical trials.

This study consists of:

* A phone/video interview or at an in-clinic visit to provide e-consent and medical history
* A single home health visit or subsequent in-clinic visit to collect blood sample for antibody testing
* A phone/video call for communication of AAV8 antibody test results

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Duchenne Muscular Dystrophy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AAV8 DetectCDx

An in vitro diagnostic assay to detect antibodies to AAV8 in human serum specimens.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males at least 0 to \<25 years of age
* Diagnosis of DMD
* Provision of signed and dated informed consent form (ICF) and assent as required per local regulations or requirements

Exclusion Criteria

* Prior participation in a gene therapy trial OR recipient of a gene therapy drug
Minimum Eligible Age

0 Years

Maximum Eligible Age

25 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

REGENXBIO Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rare Disease Research

Atlanta, Georgia, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Patient Advocacy

Role: CONTACT

(833) 711-0349

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Lily Goggans

Role: primary

470-600-9134

Maureen Ikpeoha

Role: backup

470-666-1884

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RGX-202-0101

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Diagnostic Test for Dementia With Lewy Bodies
NCT05479552 ACTIVE_NOT_RECRUITING
Study Evaluating MYO-029 in Adult Muscular Dystrophy
NCT00104078 COMPLETED PHASE1/PHASE2
Study of Eteplirsen in DMD Patients
NCT02255552 COMPLETED PHASE3